Trelegy vs Symbicort vs Breo Ellipta: COPD Inhaler Cost Comparison for 2026

Trelegy Ellipta, Symbicort, and Breo Ellipta are three of the highest-volume maintenance inhalers prescribed for chronic obstructive pulmonary disease (COPD) in the United States, and each represents a different tier of the treatment ladder. Trelegy Ellipta combines fluticasone furoate, umeclidinium, and vilanterol in a single once-daily inhaler, making it the only triple-combination therapy (ICS/LABA/LAMA) of the three, typically prescribed for more advanced COPD. Symbicort (budesonide/formoterol) and Breo Ellipta (fluticasone furoate/vilanterol) are both dual-combination ICS/LABA inhalers used for earlier-stage maintenance treatment. GSK manufactures both Trelegy and Breo using the same Ellipta dry-powder device, while AstraZeneca manufactures Symbicort as a pressurized metered-dose inhaler. Those device and formulation differences do not change how each drug is billed, but the three inhalers have sharply different generic status, IRA negotiation status, and manufacturer assistance programs in 2026, which is why comparing them side by side matters more for your wallet than which device you use.

The Inflation Reduction Act of 2022, signed August 16, 2022, authorized CMS to negotiate Medicare drug prices directly with manufacturers. Trelegy Ellipta and Breo Ellipta were both selected for Round 2 of that negotiation on January 17, 2025, and their Maximum Fair Prices of $175 and $67 per month take effect January 1, 2027. CMS reported that roughly 1.3 million Medicare beneficiaries use Trelegy Ellipta and about 626,000 use Breo Ellipta, which drove their selection as high-spend Part D drugs. Symbicort was excluded from the negotiation process entirely because generic budesonide/formoterol had already launched under the Breyna brand in March 2022, and the statute bars CMS from selecting drugs that already face meaningful generic competition. That single distinction, generic availability, is the biggest driver of the 2026 cost gap between Symbicort and its two brand-protected competitors, and it means Symbicort patients should focus on generic substitution rather than waiting for a negotiated Medicare price that will not arrive for this drug.

Patients switching between these three inhalers for cost reasons should talk to their prescriber first, since Trelegy's triple-therapy formulation is not clinically interchangeable with the dual-combination Symbicort or Breo. All three drugs are self-administered at home through retail or mail-order pharmacies, so all three are billed under Medicare Part D, not Part B, and none carries an HCPCS J-code. None of the three is a biologic, so no biosimilar exists or is expected for any of them; the biosimilar approval pathway applies only to large-molecule drugs, not to these small-molecule inhaled combinations. The comparison table below lays out cash price, Medicare Part D treatment, generic availability, and manufacturer patient assistance program for all three inhalers side by side.

What COPD Inhaler Comparison Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same copd inhaler comparison can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Hospitals rarely bill Trelegy Ellipta, Symbicort, or Breo Ellipta as standalone pharmacy line items when a dose is given during an inpatient stay. Instead, doses of any of the three inhalers given while admitted are bundled into the Diagnosis-Related Group (DRG) payment Medicare pays the hospital for that admission, regardless of which specific inhaler was used. Private insurers negotiate their own bundled inpatient rates separately from any single drug's retail price. Patients who see a separate itemized charge for one of these inhalers on a hospital bill should treat it as a likely billing error and request an itemized review.

Medicare Part A stops paying for any of the three inhalers the moment a patient is discharged, and coverage shifts entirely to Medicare Part D for the outpatient prescription. That transition is where the 2027 IRA Maximum Fair Price for Trelegy Ellipta ($175/month) and Breo Ellipta ($67/month) will kick in, along with standard Part D formulary tier cost-sharing for Symbicort. Patients discharged on a new COPD inhaler prescription without an active Part D plan often face sticker shock at the outpatient pharmacy because they assumed the inpatient DRG rate would carry over. Anyone leaving the hospital on Trelegy, Symbicort, or Breo without Part D coverage should call 1-800-MEDICARE before the first fill.

Generic budesonide/formoterol, sold as Breyna since March 2022, remains the lowest-cost fallback across all three inhaler scenarios at $97 to $223 per month with a discount coupon, roughly 60 to 80 percent below the Symbicort brand cash price. None of the three inhalers compared here is a biologic, so the biosimilar approval pathway that lowers costs for drugs like Humira or Stelara simply does not exist for fluticasone furoate, budesonide, or their paired bronchodilators; cost reduction for these three drugs comes only through small-molecule generic competition, IRA negotiation, or manufacturer patient assistance. Patients who cannot afford Trelegy or Breo should ask their prescriber whether a step-down to generic budesonide/formoterol is clinically appropriate rather than skipping doses, since untreated COPD exacerbations can lead to costly hospitalizations.

Patient Assistance Programs

GSK and AstraZeneca each run separate patient assistance programs for their inhalers, and the eligibility structure differs meaningfully between the two manufacturers. If you have no insurance and a modest income, the cost of your COPD inhaler may be $0 through the correct manufacturer program, but you must apply to the manufacturer of your specific prescribed drug; there is no single combined COPD inhaler assistance program covering all three.

Medicare Part D

Medicare Part D treats these three inhalers very differently starting in 2027. Trelegy Ellipta and Breo Ellipta will be subject to the IRA Maximum Fair Price of $175 and $67 per month respectively, applied at any network pharmacy regardless of which specific plan you carry. Symbicort has no negotiated price; your out-of-pocket cost depends entirely on your Part D plan's formulary tier for brand Symbicort versus generic budesonide/formoterol, and most plans place the generic on a much lower tier with a smaller copay than the two IRA-negotiated brands. In 2026, before the negotiated prices take effect, all three inhalers are covered under standard Part D formulary rules. All out-of-pocket spending on any of the three drugs counts toward the same 2026 Part D annual out-of-pocket cap of $2,100; once you hit that cap across all your Part D drugs combined, you pay $0 for the rest of the calendar year.

Prior authorization and step therapy are common Part D requirements for Trelegy Ellipta and Breo Ellipta, meaning patients may need to document that they tried a lower-cost ICS/LABA combination, such as generic budesonide/formoterol, before a plan will cover the triple-combination or brand dual-combination inhaler. Extra Help (the Part D Low Income Subsidy) reduces cost-sharing further for beneficiaries with limited income and resources. In 2026, Extra Help enrollees pay a small copay per fill for brand-name inhalers and less for generic budesonide/formoterol. Extra Help is generally available to beneficiaries with income at or below 150% of the Federal Poverty Level. Apply through the Social Security Administration at 1-800-772-1213 or at ssa.gov.

Common COPD Inhaler Comparison Billing Errors

All three COPD inhalers are self-administered and billed through Part D or a commercial pharmacy benefit rather than Part B, so most billing problems appear on pharmacy claims or Explanation of Benefits statements rather than hospital bills. Watch for these issues:

• Pharmacy charges more than the $175 Trelegy or $67 Breo IRA Maximum Fair Price for a Medicare Part D fill starting in 2027, which violates federal law; ask your plan's member services to reprocess the claim.
• Generic budesonide/formoterol billed at the Symbicort brand-name price instead of the generic tier.
• Manufacturer savings card (GSK's $35 program or AstraZeneca's Symbicort Affordability Program) applied for a patient who has Medicare or Medicaid, which is prohibited and can result in a claim clawback later.
• Step therapy denial requiring a generic budesonide/formoterol trial without documenting that the generic was already tried and failed or is clinically inappropriate.
• Wrong strength or wrong inhaler billed, for example Symbicort's 160/4.5mcg strength billed when the 80/4.5mcg was dispensed, or Breo billed when Trelegy was actually filled, which can trigger an incorrect copay.
• Charged the standard copay after you already hit the $2,100 Part D annual out-of-pocket cap for the year across all your combined Part D drugs.

Frequently Asked Questions